Aprea to provide poster on phase We/II clinical trial of APR-246 anticancer substance at ASCO Meeting Among a lot more than 5000 poster abstracts, Aprea AB has been selected to provide a poster at the annual American Society of Clinical Oncology Meeting in Chicago. The demonstration will explain the scientific rational and design of the ongoing phase I/II medical trial with Aprea’s drug candidate APR-246. Aprea’s drug applicant APR-246 belongs to a fresh class of anticancer substances shown to induce programmed cell loss of life through a p53 mediated mode of action major effect . The compound happens to be being tested in a phase I/II clinical trial at seven treatment centers in Sweden. The study includes 24 patients approximately, and can be an open labeled, dose-escalating study on mainly blood malignancy patients, but also sufferers with prostate cancer.
The purpose of the scheduled program is normally to catalyze the discovery of innovative biomarkers that aid in early diagnosis, detection and disease monitoring of Lewy body dementias. Lewy body dementias will be the second most common type of degenerative dementia in the elderly, affecting an estimated 1.3 million people in the United States. Yet many individuals who’ve LBD are misdiagnosed, mostly with Alzheimer’s or Parkinson’s illnesses. Developing effective biomarkers is key to helping to correctly diagnose the disease, monitor disease progression and develop effective new drugs to treat, prevent and cure LBD.